Please login to the form below
tuberculosis
This page shows the latest tuberculosis news and features for those working in and with pharma, biotech and healthcare.
Evotec says Sanofi deal makes it anti-infectives powerhouse
regulatory approvals of course – and that will give it “the highest qualified translational footprint in infectious disease research globally.”It will focus initially on antimicrobial resistant (AMR) infections, tuberculosis, and malaria,
Latest news
-
Gates’ non-profit biotech for poverty diseases sets out its stall at BIO
Dedicated to the development of products to treat malaria, tuberculosis and diarrhoeal diseases and with a war chest from its parent of $273m over four years, Gates MRI has been in
-
Pharma must do more on antibiotic resistance, Davos meeting hears
for AMR and bring them to market responsibly, ”citing the case of J&J’s new tuberculosis drug bedaquiline which is available in 100 countries with tight control of access.
-
J&J expands its TB research programme
Johnson and Johnson (J&J) has partnered with the Institute of Microbial Technology (IMTECH), part of the Council of Scientific and Industrial Research (CSIR), to develop new treatments for tuberculosis (TB).
-
Just 20% of people living with hep C are aware of their status
The number of deaths attributed to viral hepatitis is comparable to those caused by tuberculosis and higher than those caused by HIV, but deaths from hepatitis are increasing while tuberculosis and
-
Dosing of GSK's malaria vaccine due to start in 2018
The Global Fund to Fight AIDS, Tuberculosis and Malaria has just approved $15m in funding for the malaria vaccine pilots, that according to the WHO assures full funding for the first
More from news
Approximately 16 fully matching, plus 127 partially matching documents found.
Latest Intelligence
-
30 women leaders in UK healthcare (part 3)
and tuberculosis around the world.
-
The cultural construction of illness
and ‘consumptive’appearance, driven by the perception of a link between tuberculosis and creativity.
-
Reactivating drug research programmes
One research-led breakthrough to hit the headlines involves the use of genome sequencing to isolate different strains of tuberculosis (TB), allowing the disease to be diagnosed more quickly.
-
Deal Watch February 2016
acquisition - company. 7, 200. Alere/Abbott Laboratories. portfolio of point of care diagnostics for infections such as HIV, tuberculosis, malaria, dengue.
-
Searching for health
We bring products to the market regularly.”. Success in HIV and multi-drug resistant tuberculosis are the highlights but Quiles is conscious of the need to translate innovation into market penetration.
More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.
Latest appointments
-
Former Merck & Co exec to lead Seres
In total Dr Pomerantz has been involved with the development of eight approved drugs for infectious diseases, covering HIV, hepatitis C and tuberculosis.
-
GlycoVaxyn appoints Gerd Zettlmeissl as chairman
He currently serves on the boards of several biotechnology companies including Aeras, an organisation dedicated to the development of tuberculosis vaccines.
-
Former PEPFAR head Mark Dybul to lead the Global Fund
Former PEPFAR head Mark Dybul to lead the Global Fund. Joins at time of change for the AIDS, tuberculosis and malaria focused non-profit organisation. ... The Global Fund to Fight AIDS, Tuberculosis and Malaria has appointed renowned AIDS expert Dr Mark
More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Could ketamine be the next big thing in depression?
Doctors noticed that tuberculosis patients treated with isoniazid showed signs of improved mood.
-
Exploring MINT: Part 4 - Turkey
In Eastern Turkey, outbreaks of communicable diseases such as tuberculosis are still occurring.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Client Services Director - Med Comms
-
Great salary and bebefits
-
Account Manager
-
£40, 000 - £45, 000 benefits
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Business Unit Head, Medical Communications, London
-
Excellent package
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
Subscribe to our email news alerts
- Brexit rebels win vote on European Medicines Agency alignment
- AstraZeneca joins Merck in Brexit stockpiling effort
- NHS England to Vertex: come clean on Orkambi offer
- Moving annual total (MAT)
- Vyriad inks immunotherapy alliance with Merck/Pfizer
- J&J’s Invokana aces diabetic kidney disease trial, setting up filings
- Shining brighter than ever
- China’s BeiGene takes PD-1 antibody into pivotal trials
- Sangamo bulks up in cell therapy with TxCell acquisition
- Random42 win Creativity International Award for Scientific Animation
- Merck & Co joins big pharma pricing pledge – but sceptics unconvinced
- Aurora partners with PIPHealth and taps into patient panels
PMHub
Hanson Zandi
Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
